Benchmark PLC, the aquaculture biotechnology business, said results for the year to September just ended will be significantly ahead of market forecasts after all three arms performed ahead of target.
The current consensus is for annual underlying profits (adjusted EBITDA) of £15.9mln, but Benchmark expects to do better than that.
Good momentum in the third quarter continued into the final three months, it said, helped by cost control and further recovery in its end markets.
Advanced Nutrition has been the stand-out performer, with excellent year-on-year growth, said the AIM-listed business.
Genetics had a strong end to the year while Health saw its first revenues from its sea lice treatment, Ectosan Vet and CleanTreat.
Trond Williksen, chief executive, added: "We are pleased by the continuing momentum in the business, which reflects the benefits of our clear commercial focus, having streamlined the organisation, our continued disciplined approach to cost control and good demand for our products in our recovering markets.
"As a focused aquaculture biotechnology company with three strong business areas, we are well-positioned to capture market opportunities and deliver profitable growth."
Results for the year ended 30 September 2021 will be announced on 29 November 2021.